Pulmicort Turbuhaler Receives Approvable Letter From the FDA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Pulmicort Turbuhaler Receives Approvable Letter From the FDA

WESTBOROUGH, Mass., June 18, 1996 -- Astra has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for Pulmicort Turbuhaler, the company's breath-activated dry-powder corticosteroid inhaler. The product is to be marketed through Astra's wholly owned subsidiary Astra USA, Inc.

"This is an important milestone in the process of making our product available for prescription in the United States. We are pleased that our application has reached this stage of regulatory review and are working with the FDA to address their remaining questions," said Jan Larsson, President and CEO of Astra USA.

Astra's Pulmicort(TM) is currently the largest selling anti-asthma agent in Europe, where the product has benefited from the recognition of asthma as an inflammatory condition in the airways.

Astra AB (NYSE: ASTRA) is one of the world's fastest growing pharmaceutical companies, employing approximately 17,000 persons in 40 countries. Astra USA markets such prescription products as RHINOCORT(R) (budesonide) Nasal Inhaler, TOPROL-XL(TM) (metoprolol succinate), XYLOCAINE(R) (lidocaine), FOSCAVIR(R) (foscarnet) and EMLA(R) Cream.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities